Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (1393)	8/4/2000 8:10:33 PM
From: John Metcalf	Read Replies (1) \| Respond to of 52153

I'm in the R&D-should-be-capitalized camp. It's easy to see the asset when it eventually becomes a drug or marketed product, but harder to see the asset when it is R&D in process. In fact, Scott can't seem to see this asset at all-:) Irrespective of whether R&D has produced a patent asset or a product asset, there are intermediate steps of achievement along the way -- say new animal disease models, newly noticed correlated events, new assays, production methods, etc. These learning curve elements expand the company's capability beyond the product under development and surely add to value, at least as viewed by an acquirer.